STAT3 and prostate cancer: Our findings also indicate that the application of STAT3 inhibitors may resensitize prostate cancer cells to chemotherapy and that, given the role of STAT3 activity in the progression of a wide range of cancers, the mechanism described herein may have broad applicability to other skeletal malignancies and/or metastases.